Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171.HK) expects a reduction in net loss and adjusted net loss for the fiscal year ending December 31, 2025, primarily due to the commercialization of its drug, Zeworkiobulin Injection, and the acceptance of the New Drug Application (NDA) for Shurikiobulin Injection by the National Medical Products Administration (NMPA) [1]. Financial Summary - The net loss for the fiscal year 2025 is projected to be no more than approximately RMB 120 million, a significant decrease from approximately RMB 798 million for the fiscal year ending December 31, 2024 [1]. - The adjusted net loss, which excludes share-based compensation, is expected to be no more than approximately RMB 95 million, down from approximately RMB 789 million for the fiscal year ending December 31, 2024 [1]. Contributing Factors - The reduction in losses is attributed to several factors, including: - Increased commercialization revenue from Zeworkiobulin Injection in mainland China [1]. - Impact of foreign exchange fluctuations [1]. - Significant reduction in research and development expenses for both Zeworkiobulin Injection and Shurikiobulin Injection [1].
科济药业-B(02171.HK)：2025年度预计集团将出现净亏损和经调整净亏损同比减少